0001209191-17-046026.txt : 20170721 0001209191-17-046026.hdr.sgml : 20170721 20170721200226 ACCESSION NUMBER: 0001209191-17-046026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170719 FILED AS OF DATE: 20170721 DATE AS OF CHANGE: 20170721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chodakewitz Jeffrey CENTRAL INDEX KEY: 0001610876 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 17977406 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL ST., SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-07-19 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2017-07-19 4 M 0 6303 96.87 A 128814 D Common Stock 2017-07-19 4 M 0 32343 109.14 A 161157 D Common Stock 2017-07-19 4 S 0 39833 161.00 D 121324 D Common Stock 2017-07-21 4 S 0 700 158.08 D 120624 D Common Stock 2017-07-21 4 S 0 1000 158.92 D 119624 D Common Stock 2017-07-21 4 S 0 400 159.85 D 119224 D Common Stock 2017-07-21 4 S 0 3464 161.38 D 115760 D Common Stock 2017-07-21 4 S 0 1336 162.04 D 114424 D Stock Option (Right to Buy) 96.87 2017-07-19 4 M 0 6303 0.00 D 2024-07-14 Common Stock 6303 6875 D Stock Option (Right to Buy) 109.14 2017-07-19 4 M 0 32343 0.00 D 2025-02-02 Common Stock 32343 25157 D Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $158.08 (range $157.48 to $158.41). Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $158.92 (range $158.61 to $159.48). Open market sales reported on this line occurred at a weighted average price of $159.85 (range $159.64 to $160.25). Open market sales reported on this line occurred at a weighted average price of $161.38 (range $160.90 to $161.89). Open market sales reported on this line occurred at a weighted average price of $162.04 (range $161.90 to $162.38). The option vests in 16 quarterly installments from 7/15/2014. The option vests in 16 quarterly installments from 2/3/2015. /s/ Omar White, Attorney-in-Fact 2017-07-21